Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000632180 | SCV000753285 | pathogenic | Mucopolysaccharidosis, MPS-II | 2022-06-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Experimental studies have shown that this missense change affects IDS function (PMID: 9573369, 26407519). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt IDS protein function. ClinVar contains an entry for this variant (Variation ID: 527322). This missense change has been observed in individual(s) with mucopolysaccharidosis (MPS) type II (PMID: 7728156, 9573369, 10215411, 17063374, 22976768, 24515576, 28077157). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 86 of the IDS protein (p.Pro86Leu). |
| Ambry Genetics | RCV002458004 | SCV002739598 | pathogenic | Inborn genetic diseases | 2018-06-05 | criteria provided, single submitter | clinical testing | The p.P86L pathogenic mutation (also known as c.257C>T), located in coding exon 3 of the IDS gene, results from a C to T substitution at nucleotide position 257. The proline at codon 86 is replaced by leucine, an amino acid with a few similar properties. This mutation has been detected in several individuals with Mucopolysaccharidosis type II (MPS II; also called Hunter syndrome) (Popowska E, et al. Hum. Mutat. 1995;5(1):97-100; Vafiadaki E, et al. Arch. Dis. Child. 1998 79(3):237-41; Isogai K, et al. J. Inherit. Metab. Dis. 1998;21(1):60-70; Lampe C et al. JIMD Rep, 2014 Mar;14:99-113; Kosuga M et al. Mol. Genet. Metab., 2016 07;118:190-7), and occurred de novo in at least one individual (Chiong MA et al. Orphanet J Rare Dis, 2017 01;12:7). In addition, several functional studies have shown that this mutation disrupts splicing, resulting in a truncated mRNA product which causes a decrease in IDS enzymatic activity and lysosomal formation (Isogai K, et al. J. Inherit. Metab. Dis. 1998;21(1):60-70; Sukegawa-Hayasaka K, et al. J. Inherit. Metab. Dis. 2006 Dec; 29(6):755-61; Matos L et al. Biochim. Biophys. Acta, 2015 Dec;1852:2712-21; Millat G et al. Biochim. Biophys. Acta, 1998 Mar;1406:214-8). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Revvity Omics, |
RCV000632180 | SCV003825323 | pathogenic | Mucopolysaccharidosis, MPS-II | 2022-06-29 | criteria provided, single submitter | clinical testing |